US 7,569,536 B2
Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
Masatoshi Hagiwara, 912-8, Naniwa-cho, Hanamigawa-ku, Chiba-shi, Chiba 262-0024 (Japan); Takeshi Fukuhara, Tokyo (Japan); Masaaki Suzuki, Aichi (Japan); and Takamitsu Hosoya, Kanagawa (Japan)
Assigned to Masatoshi Hagiwara, Chiba (Japan)
Appl. No. 10/584,482
PCT Filed Dec. 24, 2004, PCT No. PCT/JP2004/019393
§ 371(c)(1), (2), (4) Date Mar. 02, 2007,
PCT Pub. No. WO2005/063293, PCT Pub. Date Jul. 14, 2005.
Claims priority of application No. 2003-435085 (JP), filed on Dec. 26, 2003.
Prior Publication US 2007/0135367 A1, Jun. 14, 2007
Int. Cl. A01N 61/00 (2006.01); A61K 51/00 (2006.01); C12N 15/09 (2006.01); C12N 9/12 (2006.01)
U.S. Cl. 514—1  [424/9.1; 424/9.2; 435/69.2; 435/194] 7 Claims
 
1. A method for the treatment of a viral infection in a subject in need thereof, comprising administering to the subject in need of treatment for the viral infection, in an amount effective to treat the viral infection, an aniline derivative represented by the following formula (I):

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt or hydrate thereof,
wherein, R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, a C2-6 alkenyl group which may have a substituent, a C2-6 alkynyl group which may have a substituent, a C6-10 aryl group which may have a substituent, a halogen atom, a nitro group, a cyano group, an azide group, a hydroxy group, a C1-6 alkoxy group which may have a substituent, a C1-6 alkylthio group which may have a substituent, a C1-6 alkylsulfonyl group which may have a substituent, a carboxyl group, a formyl group, a C1-6 alkoxycarbonyl group which may have a substituent, an acyl group, an acylamino group, or a sulfamoyl group;
R2 represents a hydrogen atom;
R3 represents a C6-10 aryl group which may have a substituent, or a nitrogen-containing heterocycle which may have a substituent;
R4 represents a hydrogen atom;
Q represents —C(O)—, —C(S)—, —SO2—, —C(S)NHC(O)—, —C(O)NHC(O)—, or —C(O)NHC(S)—;
W represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, a C6-10 aryl group which may have a substituent, a halogen atom, a hydroxy group, a C1-6 alkoxy group which may have a substituent, a C1-6 alkylthio group which may have a substituent, a nitrogen-containing heterocycle which may have a substituent, a condensed aromatic heterocycle which may have a substituent, or a group represented by the following formula (II):

OG Complex Work Unit Drawing
wherein, R5 and R6 are the same or different and each represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, a nitrogen-containing heterocycle which may have a substituent, a condensed aromatic heterocycle which may have a substituent, an acyl group, or an acylamino group;
the above R5 and R6 together with the adjacent nitrogen atom may form a heterocycle which may have a substituent, and the heterocycle may be a condensed aromatic heterocycle which may have a substituent;
the above R5 and R6 may be a cycloalkylidene amino group which may have a substituent, or an aromatic condensed cycloalkylidene group which may have a substituent, thereby treating the viral infection in the subject, and
wherein the viral infection is caused by:
(1) any one of the following RNA viruses: severe acute respiratory syndrome (SARS), poliovirus, human rhinovirus, hepatitis A, C, D, and E viruses, vaccinia virus, Japanese encephalitis virus, dengue virus, human coronavirus, Ebola virus, influenza virus, or sindbis virus; or
(2) any one of the following DNA viruses: a herpes simplex virus, human adenovirus, hepatitis B virus, cytomegalovirus, EB virus, herpesvirus, human herpesvirus, smallpox virus, polyoma virus, or human papilloma virus.